Impact of medication and psychological behaviour assessment by community pharmacists in type 2 diabetes mellitus patients after hospital stay

Sudhir Singh Gangwar¹, N. Monisha², Jainaf Nachiya¹, Kanchana Narasingarao³, Parimalakrishnan. S² and Seo Pratap Singh⁴

1. Department of Pharmaceutical Sciences, GSVM Medical College, Kanpur, Uttar Pradesh, India.
2. Department of Pharmacy, Annamalai University, Annamalai Nagar, Tamil Nadu, India.
3. Andhra Yuvathi Mandali, School of Pharmacy, Barkatpura, Hyderabad, Andhra Pradesh.
4. Department of Pharmacology, GSVM Medical College, Kanpur, Uttar Pradesh, India.

Abstract
Drug related problem (DRPs) is a key factor which will affect the outcome of therapy and safety. The aim of the present study is to assess the DRPs in T2DM patients and psychological aspects of patients by community pharmacists to observe the rate of DRP. Prospective randomized controlled intervention study involved T2DM patients and conducted in two community pharmacies at Kanpur from January 2012 to December 2012. The assessment of DRPs was based on the PCNE. Changes in HBA₁C, LDL, BP, foot examinations, changes medical and medication utilization were studied. Using as control group, received usual care, and interventional group provided, intervened with use of the STG. Researcher provided the knowledge to community pharmacists and patients. Baseline and interventional data were collected at 0,3,6,9 and 12 months. Over 12 month study, participants’ average HBA₁C reduced from 8.9% at initial visit to 7.5%. During this time, the eye examination rate was raised from 31% to 48%, and the foot examination rate was raised from 35% to 50%. It may be concluded that the intervention of pharmacists showed very less significant influence on any of the intermediate health outcomes in T2DM.

Keywords: Type 2 Diabetes Mellitus, Drug related problems, PCNE classification, Medication review, Psychological behavior.

DOI:http://dx.doi.org/10.4314/ahs.v14i3.7

Introduction
The type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterised by defects in insulin secretion and/or insulin resistance. It forms part of a cluster of cardiovascular risk factors seen in at higher rates in patients with T2DM, which is characterised as the metabolic syndrome. That includes central obesity, hypertension and/or dyslipidaemia etc. (Carrera Boada. CA and Martínez-Moreno. JM, 2013) India is the leading country in the world with the greatest number of diabetes patients. According to the International Diabetes Federation (IDF) atlas 2012, the cases recorded for T2DM were 63,013.87 (in 1000s), diabetic related deaths constituted for 1,013,057 and undiagnosed cases of T2DM were 32,184.34 (in 1000s). (Whiting. DR et al 2011 and Anjana RM et al 2011) Hypertension is the most common co morbidity in T2DM patients, with a prevalence rate up to two-thirds of the global population. Hypertension triggers the risk of cardiovascular disease in T2DM patients and also enhances the possibility of developing microvascular complications such as diabetic nephropathy and retinopathy. (Paul P. Dobesh, 2006)

Patients with any illness or disease along with another precipitating co morbidity condition often receive multiple medications which often lead to the occurrence of drug-related problems (DRPs). (Zaman Huri and Fun Wee, 2013) A DRP is an event or circumstance involving drug therapy that actually or potentially interferes with desired health outcomes. There is a high prevalence rate of DRPs that has been observed in T2DM patients. DRPs may lead to additional complications that may lead to significant morbidity or mortality, prolonged hospitalization, and increased health care expenditure. Several problems and causes of DRPs in T2DM patients with hypertension and factors influencing will be reported in the study. (Rashed. AN et al, 2012 and) To date, polypharmacy (≥5 concurrent medications), age status (≥ 65 years old), multiple medical conditions and renal impairment have been shown to be the most causing influencing factors.
Drug-related problems affect the outcomes on morbidity, mortality and cost which constitute a major public health problem. Most people with diabetes live in low- and middle-income countries like India, and these countries will also see the greatest increase over the next 19 years. The recently published ICMR-INDIAB national study reported that there are 62.4 million people with T2DM and 77 million people with pre-diabetes in India. These numbers are projected to increase to 101 million by the year 2030. (Whiting DR et al, 2011 and Anjana RM, et al, 2011) The prevalence of diabetic retinopathy was 17.6%, microalbuminuria in 26.9% neuropathy was 26.1%, coronary artery disease (CAD) was 21.4% and peripheral vascular disease was 6.3%. (V. Mohan et al, 2013).

Objective
The objective of this study is to assess causes and factors of DRPs in T2DM patients with any comorbid conditions so as to enhance therapeutic outcome by implementing effective medication review and psychological aspects in the treatment plan.

Methods
Study Design
The study was designed as a prospective randomized controlled intervention involving 723 participants with a follow up of one year. The intervention was performed by trained community pharmacists with the help of researchers. The Independent Human Ethics Committee in Ahmedabad (Approval No.: IRB00005741), India has approved the present study design, protocols, information letters and informed consent form.

Study Setup
The trial was conducted in 2 community pharmacies at Kanpur, Uttar Pradesh, India [Anna Hajare Medical Clinic and Anjali Hospital & Nursing Home, Kanpur]. The present study was performed by 8 trained pharmacists in association with diabetologist. The patients were counseled in the both pharmacies randomly by the trained community pharmacists.

Study Population
723 participants were enrolled into the study those regularly visit in the both pharmacies. Participants were between 20 and 75 years of age, the prescriptions which contain antidiabetic agent(s) prescribed from the TNSTG were only considered as eligible to participate in the study. The researcher was identified the prescription and obtained written informed consent from participants before study starts.

Inclusion criteria
1. Patients with diagnosis of T2DM for > 1 year prior to entry in the study willing and able to complete the questionnaire and on pharmacotherapy
2. Patients who are currently treated with a single or combination of injectable/oral antidiabetic drugs with or without insulin therapy
3. Treatment type must be unchanged in the previous 3 months. However, dose modifications are allowed
4. Patients who agree to participate in the study and give their written informed consent
5. Patients aged between above 20 and below 75 years old.

Exclusion criteria
1. Patients with type 1 diabetes.
2. Patients with diabetic ketoacidosis and/or hyperosmolar hyperglycaemic state.
3. Patients with secondary diabetes, including disease of the exocrine pancreas, endocrinopathies.
4. Patients with concurrent treatment involving systemic glucocorticoids. However, inhaled, locally injected and topical use of glucocorticoids is allowed.
5. Patients suffering from severe cardiac, hepatic, renal diseases as judged by the investigator.
6. Any condition of the patient which may have an impact on objective and outcome of the trial example: patients currently undergoing major/ minor surgical

Data collection
Demographic characteristics such as age, gender, education level, income, height, weight, and body mass index were recorded. Clinical characteristics such as duration of hospital stay, duration of T2DM, presence and duration of comorbidities and presence of diabetic complications. Laboratory results and concurrent medications were also collected.

Study procedures
Medication review
In the intervention group medications of patients were reviewed by the trained community pharmacists by utilizing their prescription and the patient's medication evaluation profile. When prescribed by a medical specialist, details about the indication for the drug will
be obtained from BNF (British National Formulary, 2010) and TNSTG (Standard Treatment Guidelines, 2010). Participants were motivated to adhere for their therapy regimen though motivational interviews.

The authors identified and classified the DRPs by using PCNE. (PCNE Classification scheme for Drug related problems V5.01) PCNE is a recognized, which has been reviewed for several times and tested for its validity and reproducibility. In the present study, PCNE was classified for DRPs as 6 domains and utilized in identifying the probable reasons from the patient's prescription with the help of STGs and literatures also. The DRPs was assessed for the appropriateness of – drug indications, drug and dosage, probable drug interactions, ADR and contraindications with three references. Causes for DRP was assessed and intervened. Recommendation was communicated to the physician and changes made. The incidences of DRPs were discussed with the diabetologist and appropriate new therapy was initiated for those having DRPs. The interview on medication review was conducted for 10 – 15 minutes for each patient to identify the complexity of the medication regimen and problems detected. The control group was given usual treatment.

**Psychological Aspect treatment**
The intervention group was provided with psychological aspect treatment (PAT) at baseline and 3, 6, 9 and 12 months by trained pharmacists, with a structured interview and motivational interviewing skills at both the study sites. The first session was conducted within one week of selection of participants for the study. The patient was informed on the contraindications, indications, side effects, administration and frequency of the medicine(s). Patients were counseled in-line with the motivational interviewing strategies to improve their medication adherence. OTC medicines were also taken into the consideration for medication review during the study period. For the PAT 25 to 30 minutes were conducted for each patient during every two visits. For the control group no PAT test was performed. (Frank Petrak et al, 2005)

**Workshop for Community Pharmacists**
Four sessions were conducted for the community pharmacists who were participated in this study on the above parameters. They were explained about the background of medication review, DRP score forms and evaluation pattern during the sessions. The pilot study was conducted to minimize the variability while assessing DRP score and reviewing the medication among the trained pharmacists. The assessed review on medication by trained pharmacist was reassessed by a specialist in medication review. The trained pharmacist was expected to identify more DRPs in interventional than control group pharmacists who was not attended the workshop on medication review. The assessment was carried out similar to that of pilot study. During one day workshop all the pharmacists were explained on motivational interviewing and decision making as well as communication skills.

**Outcome Measures**

**Primary outcome measures**
At the end of the study period researcher and coauthors calculated the incidences of DRP and compared the primary outcome with baseline, control and intervention groups by using a checklist which includes common drug problems. Among the enrolled patients DRPs were assessed and documented by conducting the structured interview and medication review was carried out the study participants (pharmacists).

**Medication Adherence with Therapy**
The 8-item self-report Morisky Medication Adherence Scale (MMAS) was used to assess medication adherence. (Morisky. DE et al, 1986)

**Secondary outcome measures**
Secondary outcomes include fasting plasma glucose level, hypoglycaemic episodes, morbidity, adverse effects and total incidence of patient visit to diabetologist for consultation of probable drug related problem during the study period was measured. The incidence of clinic visit was obtained from the prescriptions. ADR causality assessment was carried out by using Naranjo’s scale and assessed by the coauthors. (Naranjo. CA, et al, 1981) All participants completed 4 validated questionnaires during the study period. The first questionnaire was given to the participants 7 days initial to the first counselling. The second questionnaire was given at 6 months; the third questionnaire was given at 9 months and the fourth was given at 12 months.

**Sample size**
The incidence of DPRs was weighed with respect to primary outcome of the medication review and patient counseling. From the literature review, 25% of control group patients were encountered with DRPs and 30% of DRPs were decreased due to intervention. In a type 1 error of 0.05, a power of 90%, and a ratio
of one between both groups of patients, multilevel randomisation resulting in a loss of power of 10%, a total of 800 patients was needed to show a statistically significant difference.

**Statistical Analysis**

Descriptive analysis was done for the demographic characteristics of patients and other control variables both groups. Difference was tested using chi-square or t-tests. To test the effect of the intervention a multilevel design was used. Medication event was clustered within patients, and patients are clustered within pharmacies. The primary outcome, the adherence, is the dependent variable. To assess the impact of the intervention, multilevel linear and logistic regression analysis was conducted to study differences in outcome measures among patients of the intervention and control groups.

All independent variables of importance, for example socio-demographic factors and medication regimen, are included in the model to adjust for these variables. Data are analysed with SigmaStat for Windows (Demo Version) and differences in changes among the group were measured with 95% confidence intervals.

**Results**

Over 12 month study, participants’ average HBA1c reduced from 8.9% at initial visit to 7.5%, average LDL was reduced from 124.1 mg/dL to 109.6 mg/dL, and average BP was reduced from 141.5 mm Hg to 132.7 mm Hg. During this time, the eye examination rate was raised from 31% to 48%, and the foot examination rate was raised from 35% to 50%. Only 48.25% of participants were satisfied diabetes care was better from 45.5% of participants in the highest range at baseline to 51.30% at this level after 12 months (Table No.1).

| Table No. 1: Demographic and clinical characteristic of the patients (N = 723) |
|---------------------------------------------------------------|
| Characteristics | No. of patients (%) |
|------------------|---------------------|
| **Gender**       |                     |
| Male             | 389 (50.80)         |
| Female           | 334 (49.20)         |
| **Age**          |                     |
| Non-elderly      | 427 (59.10)         |
| Elderly          | 296 (40.90)         |
| **Duration of hospital stay**                               |
| Not more than 7 days | 515 (71.23)        |
| 8 to 14 days     | 157 (21.72)         |
| More than 15 days | 051 (07.05)         |
| **Duration of type 2 diabetes mellitus**                    |
| Not more than 10 years | 247 (34.16)        |
| 11 to 20 years   | 224 (30.98)         |
| 21 to 30 years   | 108 (14.94)         |
| Unknown duration | 070 (09.68)         |
| **Duration of hypertension**                                |
| Not more than 10 years | 209 (28.91)        |
| 11 to 20 years   | 178 (24.62)         |
| 21 to 30 years   | 162 (22.41)         |
| Unknown duration | 174 (24.01)         |
| **HbA1c**        |                     |
| Achieved target (&lt; 6.5) | 210 (24.04)       |
| Did not achieve target (≥ 6.5) | 513 (45.96)      |
| **Diabetic complications†**                                |
| Diabetic retinopathy | 84 (11.62)         |
| Diabetic foot ulcer | 118 (16.32)        |
| Diabetic neuropathy | 073 (10.10)        |
| **Comorbidities‡**                                        |
| Renal impairment   | 94 (13.00)          |
| Cardiovascular disease | 123 (17.01)       |
| Dyslipidemia       | 104 (14.38)         |
| Stroke             | 051 (07.05)         |
| Gastrointestinal disease | 012 (1.66)       |
| Liver impairment and Bronchial asthma | 021 (2.90) |

† – One patient may have more than one diabetic complication
‡ - One patient may have more than one comorbidity
In the present study, the DRPs in TDM and comorbid patients observed are recorded in Table No. 2. The type of problems experienced was typically due to errors in the medication adherence and compliance. Out of the 723 patients 6.92% (n=50) of the patients experienced adverse drug reactions that were non allergic in nature, 26.96% (n=193) of them showed problems associated with choice of the drug, 16.45% of the patients developed dosing related problems, 14.94% (n=108) of the patients experienced drug use problems as they did not administer the drugs at all, 13.28% (n=96) of them showed potential drug interactions. 31.53% of the reported other problems like patient dissatisfied with therapy despite taking drug(s) correctly (3.32%) and insufficient awareness of health and diseases (26.28%) and 1.94% experienced therapy failure.

The causes of the above mentioned DRPs in T2DM with hypertension were evident in 696 patients as shown in Table No. 3. The major causes assessed were due to drug and dose selection 47.55% (n=331), drug use process such as in appropriate timing of administration, drug under administered and patient unable to use the drug or dosage form as directed. The second major cause of the DRPs in these patients were patient/ psychological associated evident in 39.65% (n=276) of the patients, followed by drug use process in 14.65% (n=102). In 8.47% (n=59) it was due to lack of proper instructions for use of drugs, unawareness of the reason for drug treatment and unable to understand the local language. 6.6% (n=46) due to logistic issues such as prescribed drug not available (anymore) and prescribing errors.

### Table No. 2: Drug related problems in T2DM patients with hypertension (n = 723)

| Code | Problems* | No. of problem (%) |
|------|-----------|--------------------|
| P1   | Adverse reactions | 45 (6.22) |
| P1.1 | Side effects suffered (non-allergic) | 50 (6.92) |
| P2   | Drug choice problems | 167 (23.10) |
| P2.1 | Inappropriate drug (not most appropriate for indication) | 64 (8.85) |
| P2.2 | Inappropriate drug form (not most appropriate for indication) | 11 (1.52) |
| P2.3 | Inappropriate duplication of therapeutic group or active ingredient | 18 (2.49) |
| P2.4 | Contraindication for drug | 59 (8.16) |
| P2.5 | No clear indication for drug use | 9 (1.24) |
| P2.6 | No drug but clear indication | 32 (4.43) |
| P3   | Dosing problems | 123 (17.01) |
| P3.1 | Drug dose too low or dosage regime not frequent enough | 8 (1.11) |
| P3.2 | Drug dose too high or dosage regime too frequent | 88 (12.17) |
| P3.3 | Duration of treatment too short | 10 (1.38) |
| P3.4 | Duration of treatment too long | 13 (1.80) |
| P4   | Drug use problems | 99 (13.69) |
| P4.1 | Drug not taken/administered at all | 108 (14.94) |
| P5   | Interactions | 133 (18.40) |
| P5.1 | Potential interaction | 96 (13.28) |
| P6   | Others | 202 (27.94) |
| P6.1 | Patient dissatisfied with therapy despite taking drug(s) correctly | 24 (3.32) |
| P6.2 | Insufficient awareness of health and diseases (possibly leading to future problems) | 190 (26.28) |
| P6.4 | Therapy failure (reason unknown) | 14 (1.94) |

*Only problems that have a frequency of more than one were included.
Table No. 3: Causes of DRPs in T2DM patients with hypertension (n = 696)

| Code | Causes* | No. of problem (%) |
|------|---------|--------------------|
| C1   | Drug/ Dose selection                  | 348 (50.0) |
| C1.1 | Inappropriate drug selection          | 140 (20.12) |
| C1.2 | Inappropriate dosage selection        | 118 (16.95) |
| C1.5 | Synergistic/preventive drug required and not given | 35 (5.03) |
| C1.8 | Manifest side effect, no other cause   | 38 (5.46) |
| C2   | Drug use process                      | 93 (13.62) |
| C2.1 | Inappropriate timing of administration and/or dosing intervals | 18 (2.59) |
| C2.2 | Drug underused/under-administered     | 73 (10.49) |
| C2.6 | Patient unable to use drug/tom as directed | 11 (1.58) |
| C3   | Information                           | 51 (7.33) |
| C3.1 | Instructions for use/taking not known  | 21 (3.02) |
| C3.2 | Patient unaware of reason for drug treatment | 19 (2.73) |
| C3.4 | Patient unable to understand local language | 19 (2.73) |
| C4   | Patient/Psychological                 | 242 (34.77) |
| C4.1 | Patient forgets to use/take drug       | 31 (4.54) |
| C4.2 | Patient has concerns with drugs        | 14 (2.01) |
| C4.3 | Patient suspects side-effect           | 21 (3.02) |
| C4.5 | Patient unwilling to bother physician  | 13 (1.88) |
| C4.7 | Patient unwilling to adapt life-style  | 68 (9.67) |
| C4.8 | Burden of therapy                      | 94 (13.50) |
| C4.9 | Treatment not in line with health beliefs | 35 (5.03) |
| C5   | Logistic                              | 14 (2.01) |
| C5.1 | Prescribed drug not available (anymore) | 33 (4.74) |
| C5.2 | Prescribing error (only in case of slip of the pen) | 13 (1.87) |

*Only causes that have frequency of more than one were included.

From Table No. 4, the factors causing the DRPs in T2DM patients with hypertension are the age of the patient, intake of number of medicines, duration of hospital stay and other comorbid conditions like microvascular complications, cardiovascular events, renal as well as liver impairment and hyperlipidaemia. In the present study, we have compared the factors and occurrence of DRPs like adverse drug reaction, drug choice problems, dosing problems Adverse drug reactions: As summarized in table no: 4, among the 375 patients; 51 of them had experienced ADRs whereas 324 of them did not. Among the group of patients who had experienced them, about 45.1% of them were elderly patients and 55.90% of them were non elderly patients. On the other hand, among the 324 who were not affected by any ADRs, 41.36% and 58.64% were elderly and non elderly respectively. Depending upon the second factor i.e., polypharmacy, 89.39% of them were taking many medicines for different conditions experienced ADRs while the rest 19.61% were not taking polypharmacy. Whereas out of those 324 who did not have any ADRs, among them 76.6% were taking polypharmacy while 23.4% of the patients were not. Considering the duration of hospital stay as one of the factor for occurrence of ADRs, 60.78% of the patients had them in the duration of ≤ 1 week, while 39.22% of them for the duration of > 1 week. In contrast with this, the ones who had not experienced ADRs, for duration of ≤1 week and > 1 week were 62.96% and 37.04% respectively. The patients living with other complications like microvascular complications, cardiovascular events, renal impairment, liver impairment and hyperlipidaemia and experienced ADRs were 58.82%, 40.06%, 54.90%, 7.84% and 41.18% respectively and the ones without these above mentioned complications but yet ADR occurrence was reported were 41.18%, 52.94%, 45.10%, 92.16% and 58.82% respectively. Among the 324 who had no ADRs but living with the above mentioned complications were 54.63%, 55.86%, 58.02%, 8.02% and 29.32% respectively, while the patients without the ADRs and also without the above complications were 45.37%, 44.14%, 41.98%, 91.98% and 70.68% respectively.
Table No. 4: Comparison between factors and occurrence of adverse reactions, drug choice problems, and dosing problems (375)

| Factors                        | Adverse reactions (n = 375) | Drug choice problem (n = 375) | Dosing problem (n = 375) |
|-------------------------------|-----------------------------|-------------------------------|--------------------------|
|                               | n (%)                       | Yes (n = 149)                  | No (n = 226)              | Yes (n = 118)                  | No (n = 257)                  |
|                               |                             | P-value                        |                          | P-value                        |                          |
| Elderly                       | Yes                         | 23 (45.10)                     | 62 (41.61)                | 73 (61.86)                     | 148 (57.59)                 | 0.5a                        |
|                               |                             | (41.36)                        | (71.24)                   | (38.14)                        | (42.41)                     |                            |
|                               | No                          | 28 (55.90)                     | 87 (58.39)                | 45 (38.14)                     | 109 (42.41)                 |                            |
|                               |                             | (58.64)                        | (28.76)                   | (38.14)                        | (28.76)                     |                            |
| Polypharmacy                  | Yes                         | 41 (89.39)                     | 120 (80.54)               | 90 (76.7)                      | 193 (75.08)                 | 0.1a                        |
|                               |                             | (76.6)                         | (76.45)                   | (76.7)                         | (75.08)                     |                            |
|                               | No                          | 10 (19.61)                     | 29 (19.46)                | 37 (31.36)                     | 56 (21.79)                  |                            |
|                               |                             | (23.4)                         | (23.45)                   | (31.36)                        | (21.79)                     |                            |
| Duration of hospital stay     | ≤ 1 week                    | 31 (60.78)                     | 95 (63.74)                | 105 (70.47)                    | 100 (84.74)                 | 0.1a                        |
|                               |                             | (62.96)                        | (83.19)                   | (70.47)                        | (84.74)                     |                            |
|                               | > 1 week                    | 20 (39.22)                     | 54 (36.26)                | 44 (29.53)                     | 28 (23.73)                  | 0.9a                        |
|                               |                             | (37.04)                        | (16.81)                   | (29.53)                        | (23.73)                     |                            |
| Microvascular complication    | Yes                         | 30 (58.82)                     | 105 (70.47)               | 100 (84.74)                    | 154 (5992)                  | 0.1a                        |
|                               |                             | (54.63)                        | (57.96)                   | (84.74)                        | (5992)                      |                            |
|                               | No                          | 21 (41.18)                     | 44 (29.53)                | 18 (15.25)                     | 103 (40.08)                 |                            |
|                               |                             | (45.37)                        | (42.04)                   | (15.25)                        | (40.08)                     |                            |
| Cardiovascular events         | Yes                         | 24 (40.06)                     | 97 (65.10)                | 77 (65.24)                     | 158 (61.48)                 | 0.5a                        |
|                               |                             | (55.86)                        | (61.06)                   | (65.24)                        | (61.48)                     |                            |
|                               | No                          | 27 (52.94)                     | 52 (34.90)                | 41 (34.74)                     | 99 (38.52)                  |                            |
|                               |                             | (44.14)                        | (38.93)                   | (34.74)                        | (38.52)                     |                            |
| Renal impairment              | Yes                         | 28 (54.90)                     | 94 (63.09)                | 80 (67.80)                     | 126 (40.03)                 | 0.05a*                      |
|                               |                             | (58.02)                        | (37.61)                   | (67.80)                        | (40.03)                     |                            |
|                               | No                          | 23 (45.10)                     | 55 (36.91)                | 38 (32.20)                     | 131 (50.97)                 |                            |
|                               |                             | (41.98)                        | (62.39)                   | (32.20)                        | (50.97)                     |                            |
| Liver impairment              | Yes                         | 4 (7.84)                       | 16 (10.74)                | 18 (15.25)                     | 100 (84.74)                 | 0.50a                       |
|                               |                             | (8.02)                         | (9.29)                    | (15.25)                        | (84.74)                     |                            |
|                               | No                          | 47 (92.16)                     | 133 (89.26)               | 100 (84.74)                    | 241 (93.77)                 | 0.50a                       |
|                               |                             | (91.98)                        | (90.71)                   | (84.74)                        | (93.77)                     |                            |
| Hyperlipidemia                | Yes                         | 21 (41.18)                     | 41 (27.52)                | 35 (29.66)                     | 93 (36.19)                  | 0.50a                       |
|                               |                             | (29.32)                        | (27.52)                   | (29.66)                        | (36.19)                     |                            |
|                               | No                          | 30 (58.82)                     | 108 (72.48)               | 83 (70.34)                     | 164 (63.81)                 | 0.50a                       |
|                               |                             | (70.68)                        | (61.06)                   | (70.34)                        | (63.81)                     |                            |

a Computed using Continuity Correction; b Computed using Fisher’s Exact Test; * Statistically significant (p < 0.05).

Drug Choice Problems: Among the total 375 patients, 149 of them experienced DCPs while 226 did not show any kind of DCPs. Among the 149 of the patients in whom DCPs occurred, 41.61% were elderly and the rest were non elderly, 58.39%. 80.54% of them were taking polypharmacy while 19.46% were not. It was evident in the patients whose duration of stay in the hospital was for ≤1 week and > 1 week by 63.74% and 36.26 % respectively. The occurrence of DCPs in patients with microvascular complications, cardiovascular events,
renal impairment, liver impairment and hyperlipidaemia were 70.47%, 65.10%, 63.09%, 10.74% and 27.52% respectively, whereas in the patients without the above complications but still the DCPs were evident were 29.53%, 34.90%, 36.91%, 89.26% and 72.48% respectively. On the other hand, among the 226 patients who did not experience DCPs, 71.24% were elderly and 28.76% were non elderly patients. 76.45% were taking polypharmacy while 23.45% were not. About 83.19% of the patients who were hospitalized for \( \leq 1 \) week and 16.81% for \( > 1 \) week had not experienced any kind of DCPs. The patients living with the other complications like microvascular problems, cardiovascular events, renal and liver impairment and hyperlipidaemia but no DCPs were evident were 57.96%, 61.06%, 37.61%, 9.29%, 38.94% respectively and the rest of them had no complications and no DCPs.

**Dosing problems:** Among the sample size of 375, 118 of them experienced dosing problems (DPs) whereas 257 of them did not. Among the ones who experienced DPs (\( n=118 \)), 61.86% are elderly patients and remaining 38.14% of them are non-elderly patients. About 68.64% of them take Polypharmacy and the rest 31.36% of them do not.76.7% of them reported DPs within \( \leq 1 \) week of hospital stay while 23.73% of the patients within \( > 1 \) week of hospital stay. The patients in whom the DPs were evident and who were living with other complications like microvascular, cardiovascular events, renal impairment, liver impairment and hyperlipidaemia were 84.74%, 65.24%, 67.80%, 15.25% and 29.66% respectively, whereas the remaining experienced DPs but did not have any of the mentioned complications. Among the ones, in whom DPs were not seen (\( n=257 \)), 57.59% were elderly patients while the rest 42.41% were non elderly patients. 78.21% were taking Polypharmacy but 21.79% were not. In \( \leq 1 \) week or \( > 1 \) week of hospitalization, 75.08% and 24.92% respectively, the patients did not experience any DPs. With microvascular, cardiovascular, renal, liver and hyperlipidaemia complications of 59.92%, 61.48%, 40.03%, 6.22% and 36.19% respectively, the patients did not experience DPs whereas the rest of them had no complications and also no DPs.

**Drug Use Problems:** Among the 374 sample size, the patients who experienced DUPs were 97 and who did not have DUPs were 227. In both the scenarios, the majority of the patients affected were the non-elderly patients, 68.04% and 57.72% respectively but among the elderly patients, 31.96% and 42.28% respectively. The patients who are experiencing DUPs while taking polypharmacy are 68.0%, while not taking polypharmacy are 32.0% whereas, the ones not have DUPs while taking and not taking polypharmacy are 70.67% and 29.33%. The DUPs were high in the patients whose duration of stay in hospital is \( \leq 1 \) week, 75.26% compared to the ones with hospitalization for \( > 1 \) week, 24.74%. The patients with the complications like the microvascular, cardiovascular, renal impairment, liver impairment and hyperlipidaemia, in whom the DUPs were evident were 64.95%, 53.61%, 49.48%, 10.31% and 40.21% respectively.

**Drug interactions:** The patients who experienced drug interactions were 125 and who did not were 199. In this type of DRP, the majority of patients affected were from the elderly group of patients i.e., 61.60% and 58.02% respectively. The patients in whom, the drug interactions were evident while taking and not taking polypharmacy are 94.4% and 69.75% respectively. About 75.20% of them showed drug interactions in \( \leq 1 \) week of duration of stay in hospital and 24.80% within \( > 1 \) week of hospital stay. The drug interaction were reported in patients living with microvascular, cardiovascular, renal, liver and hyperlipidaemia complications by 67.20%, 82.40%, 58.40%, 1.60% and 62.60% respectively.

**Other Problems:** Overall 187 of the patients had experienced other DRPs while 137 of the patients did not. Among them the percentile of elderly patients is 61.50% and 56.93% and that of non-elderly is 38.50% and 43.06% respectively. In the patients who were taking polypharmacy, the evidence of other DRPs were high 78.61 % when compared to those who were not taking polypharmacy, 21.39%. About 72.19% of them showed other problems in duration of \( \leq 1 \) week of hospital stay and 27.81% in duration of \( > 1 \) week hospitalization. The other DRPs in patients with microvascular, cardiovascular, renal, liver and hyperlipidaemia complications are evident with the percentile of 72.73%, 65.78%, 52.94%, 6.42% and 69.89% respectively.
Table No. 5: Comparison between factors and occurrence of drug use problems, drug interactions, and other problems (375)

| Factors                    | Drug use problems | Drug interactions | Other problems |
|----------------------------|-------------------|-------------------|----------------|
|                            | Yes (n = 97)      | Yes (n = 125)     | Yes (n = 187)  |
|                            | No (n = 227)      | No (n = 324)      | No (n = 137)   |
|                            | p-value               | p-value               | p-value               |
| Elderly                    |                   |                   |                |
| Yes                        | 31 (31.96)        | 77 (61.60)        | 115 (61.50)     |
|                            | (57.72)           | (58.02)           | (56.93)        |
| No                         | 66 (68.04)        | 48 (38.40)        | 72 (38.50)      |
|                            | (57.72)           | (41.98)           | (43.06)        |
| Polypharmacy               |                   |                   |                |
| Yes                        | 69 (68.0)         | 118 (94.40)       | 147 (78.61)     |
|                            | (70.67)           | (69.75)           | (79.56)        |
| No                         | 28 (32.0)         | 7 (5.6)           | 40 (21.39)      |
|                            | (29.33)           | (30.25)           | (20.44)        |
| Duration of hospital stay  |                   |                   |                |
| ≤ 1 week                   | 73 (75.26)        | 94 (75.20)        | 135 (72.19)     |
|                            | (67.90)           | (71.91)           | (75.18)        |
| > 1 week                   | 24 (24.74)        | 31 (24.80)        | 52 (27.81)      |
|                            | (32.10)           | (28.09)           | (24.82)        |
| Microvascular complications|                   |                   |                |
| Yes                        | 63 (64.95)        | 84 (67.20)        | 136 (72.73)     |
|                            | (60.49)           | (64.20)           | (57.66)        |
| No                         | 34 (35.05)        | 41 (32.80)        | 51 (27.27)      |
|                            | (39.51)           | (35.80)           | (42.54)        |
| Cardiovascular disease     |                   |                   |                |
| Yes                        | 52 (53.61)        | 103 (82.40)       | 123 (65.78)     |
|                            | (58.33)           | (41.98)           | (54.74)        |
| No                         | 45 (46.39)        | 22 (17.60)        | 64 (34.22)      |
|                            | (41.67)           | (35.80)           | (45.26)        |
| Renal impairment           |                   |                   |                |
| Yes                        | 48 (49.48)        | 73 (58.40)        | 99 (52.94)      |
|                            | (39.51)           | (41.98)           | (51.82)        |
| No                         | 49 (50.52)        | 52 (41.60)        | 88 (47.06)      |
|                            | (60.49)           | (53.40)           | (48.18)        |
| Liver impairment           |                   |                   |                |
| Yes                        | 10 (10.31)        | 2 (1.60)          | 12 (6.42)       |
|                            | (5.25)            | (6.48)            | (5.84)         |
| No                         | 87 (89.69)        | 123 (98.40)       | 175 (93.58)     |
|                            | (94.75)           | (93.52)           | (94.16)        |
| Hyperlipidemia             |                   |                   |                |
| Yes                        | 39 (40.21)        | 78 (62.40)        | 112 (59.89)     |
|                            | (35.80)           | (57.10)           | (56.93)        |
| No                         | 58 (59.79)        | 47 (37.60)        | 75 (40.11)      |
|                            | (64.20)           | (42.90)           | (43.06)        |

a Computed using Continuity Correction; b Computed using Fisher’s Exact Test;
* Statistically significant (p < 0.05).

Discussion

The population of India is over 1000 million (1260 million in 2012). According to the International Diabetes Federation, 61.3 million people in India had diabetes in 2011. That figure is projected to rise to 101.2 million by 2030. The prevalence rate of diabetes in the urban areas of India is thought to be 9 per cent and 3 per cent approximately in the rural areas, of the total population. This statistic helps to give an idea of the scale of the problem. (Population Reference Bureau, 2012 and Global Diabetes community). The sanofi-aventis India SITE study (Screening India’s Twin
Epidemic), rolled out during 2009/2010, was a cross-sectional epidemiological study of 16,000 patients from 800 centers in Maharashtra, New Delhi, Tamil Nadu, Andhra Pradesh, West Bengal, Karnataka, Gujarat, and Madhya Pradesh. About 60 percent of the surveyed population suffered from diabetes, hypertension, or both, and 70 percent of the patients had uncontrolled diabetes. [Sanofi-aventis' India SITE study shows 62% of diabetic population in New Delhi has 'uncontrolled' diabetes. Mumbai, India: Aventis Pharma Limited; 2010.]

According to the citations in the Population Reference Bureau: 2012 World Population Data Sheet, the noncommunicable diseases (NCDs), such as cardiovascular diseases, cancers, diabetes, and chronic lung diseases, are the leading causes of death in all regions except sub-Saharan Africa. In 2008, almost two-thirds of all the deaths globally were due to NCDs. Nearly 4 out of 5 deaths from NCDs occurred in low- and middle-income countries. While the number of people suffering and dying from NCDs will continue to increase around the world over the next several decades, the greatest increases are expected in low-income countries. In South Asia, deaths due to NCDs are projected to increase from half of all deaths between 2008 and 2030. [Population Reference Bureau; 2012 World Population Data Sheet. Washington DC, USA: USAID; 2012]

DRPs the most important aspect in the pharmaceutical care. The terms such as medication errors are often used to describe this concept, but it is different from the actual understanding of DRPs. The medication errors refer to the mistakes in the process that could lead to problems in an individual whereas, DRPs can occur when prescribing, dispensing or taking/administering medicines. There are several classifications framed to understand the factors, causes and problems arising due to drugs but in this study PCNE classification for DRP is used. A DRP is an event or circumstance involving drug therapy that actually or potentially interferes with desired health outcomes. (Bob W. van Roozendaal and Ines Krass, 2009)

This study was conducted on 723 patients, out of which 389 (50.8%) were male and 334 (49.2%) were female patients. To reduce the drug related problems the causes and factors should be known. According to the PCNE classification, 6 major domains of Drug related problems in this study such as adverse drug reactions, drug choice problem, dosing problem, drug use problem, drug interactions and others were recorded. **Adverse Reactions**

The WHO defines adverse drug reaction as “a response to a drug that is noxious and unintended and occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of disease, or for modification of physiological function”. Adverse drug reaction are classified as side effects that are allergic, nonallergic or toxic. 50 patients (6.92%) reported having experienced at least one episode of reaction of any kind. In contrast with the similar studies conducted in 2 different countries, Australia based study 43 out of 148 patients (6.3%) and in Malaysia based study 25 out of 387 (6.5%) patients experienced these type of reactions, assuming that same category of anti diabetic drugs and anti hypertensive drugs were given. This kind of drug related problems can be an outcome of prescribing error, but unexpected ADRs may also occur at normal dosages of a well selected drug.

**Drug Choice Problems**

Patient gets or is going to get a wrong (or no drug) drug for their disease and/or condition. This is usually a prescribing error. These errors commonly occur due inappropriate drug selection and 140 cases were reported for the same. This category of problem was recorded 193 times. 64 out of 193 drug choice problems were due to the administration of the drugs that were inappropriate for the patient’s condition and 59 of 193 were due to contraindication of the drug, followed by others. In some patients, synergistic or preventive drug was required but the patients did not receive, reported cases were 35. The Drug choice problem contributes to 26.69% of the errors. In the Australia based study, this category of DRP contributes 30.2% of all DRPs and the most precipitating factor is no drug prescribed even when the indication of illness is clear i.e., 182 of 206 (26.7%). Whereas in Malaysia, this category of DRP contributes 22.5% of the rest DRPs, and the leading factors are inappropriate drug administration followed by contraindications of the drug.

**Dosing Problems**

This category of DRP occurs when the patient gets the right drug, but in insufficient amount than required. This can be a prescribing error or a drug use error. This occurs due to inappropriate dosage selection for which 118 reports were recorded. Dosing errors are recorded
119 times in this study constituting for 16.45% of all the DRPs. 88 out of 119 of this DRP are due to high dose or dosage regime too frequent. This is the leading contributing factor for the dosing related drug problem in the studies based in Australia (27 out of 40) and Malaysia (44 out of 62). This is a very serious factor and through monitoring is required during the period of therapy. Otherwise, the dosing related drug problems constitute to 16% and 5.9% of the overall DRPs in Malaysia and Australia respectively.

Drug Use Problems
These kinds of DRPs arise when the patient administers the wrong drug or does not take any drug. This can be drug use error, administration error and/or filling error in the pharmacy. Proper patient counseling or educating the patient about the disease and the need for treatment can help overcome this problem of medication adherence and discouraging the idea of self medication and over the counter medication can be effective in significantly reducing the risk of wrong medication. Here the risk of potential non adherence was the major factor, 108 cases were recorded contributing to 14.94% of all the DRPs. The causes of DRP due to drug use (n=102) were inappropriate timing of administration and dosing intervals 18 out of 102, drug unused or under-administered were 73 of 102 and 11 out of 102 were because patients were unable to use the medication as directed.12.9% and 3.8% was seen for potential non adherence in Malaysia and Australia respectively.

Potential Interactions
The potential drug-drug or drug-food interaction is a form of prescribing or drug-use error. 96 cases were reported in the study. The interactions identified were mostly based on established literature and evidence recorded and compiled in authenticated resources. The drug interactions contribute to about 13.28% of all the DRPs, where as in Australia and Malaysia they contribute to about 15.1% and 16.3% of the rest of the DRPs respectively.

Other Problems
The other problems reported in this study were 228, 31.53% of all the DRPs recorded. On further interviewing and assessing the data of those 288 cases, it was found that 190 of 228 had inadequate awareness about the health and disease, that could precipitate and cause long term effects, 24 of 228 were not satisfied with the therapy without any error of non adherence and 14 of 228 experienced failure of the therapy, however the reason couldn’t be noticed. By contrast, the leading cause reported in Malaysia was inadequate awareness but in Australia it was therapy failure.

Conclusion:
The findings of the study have less significant improvement in their primary and secondary outcomes. It may be concluded, therefore, that the intervention pharmacists showed no demonstrable influence on any of the intermediate health outcomes relating to metabolic control or on therapeutic adherence in T2DM that was significantly different from that exerted by the control cohort of pharmacists.

References:
1. Carrera Boada, CA and Martínez-Moreno, JM. Pathophysiology of diabetes mellitus type 2: beyond the duo “insulin resistance-secretion deficit”. Nutr Hosp, 2013; 28(Supl. 2): 78 – 87.
2. Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-21.
3. Anjana RM, Pradeepa R, Deepa M, Datta M, Sudha V, Unnikrishnan R, et al. On behalf of the ICMR–INDIAB Collaborative Study Group. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: Phase I results of the ICMR – INDIAB study. Diabetologia, 2011; 54: 3022 – 3027.
4. Paul P. Dobesh. Managing hypertension in patients with type 2 diabetes mellitus. Am J Health Syst Pharm., 2006; 63(12): 1140 – 1149.
5. Rashied. AN, Neubert. A, Tomlin. S, Jackman. J, Alhammadan. H, AlShaikh. A, Attar. A, Aseeri. M, Wilton. L and Wong. IC. Epidemiology and potential associated risk factors of drug-related problems in hospitalised children in the United Kingdom and Saudi Arabia. Eur J Clin Pharmacol., 2012; 68(12): 1657 – 1666.
6. Mohan. V, Siddharth Shah and Banshi Saboo. Current Glycemic Status and Diabetes Related Complications Among Type 2 Diabetes Patients in India: Data from theACHEIEVE Study. Suppl JAPI, 2013; 61: 12 – 15.
7. British National Formulary Joint Formulary Committee: British National Formulary, 60th Ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2010.
8. Standard treatment guidelines, a Manual for Medical Practitioners. Edition 2010. Published by: Tamil Nadu
9. Frank Petrak, Stephan Herpertz, Christian Albus, Axel Hirsch, Bernhard Kulzer and Johannes Kruse. Psychosocial Factors and Diabetes Mellitus: Evidence-based Treatment Guidelines. Current Diabetes Reviews, 2005; 1: 1 – 16.

10. Morisky. DE, Green. LW and Levine. DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986; 24: 67 – 74.

11. Naranjo. CA, Busto. U, Sellers. EM, Sandor. P, Ruiz. I, Roberts. EA, Janecek. E, Domecq. C and Greenblatt. DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther., 1981; 30(2): 239 – 245.

12. Population Reference Bureau; 2012 World Population Data Sheet. Washington DC, USA: USAID; 2012.

13. Global Diabetes community; http://www.diabetes.co.uk/global-diabetes/diabetes-in-india.html - Accessed on 01/12/12.

14. Zaman Huri and Fun Wee. Drug Related Problems in Type 2 Diabetes Patients with Hypertension: A Cross-Sectional Retrospective Study. BMC Endocrine Disorders, 2013; 13: 2.

15. PCNE Classification scheme for Drug related problems; www.pcne.org/sig/drp/documents/PCNE%20classification%20V5.01.pdf - Accessed on 01/12/2012.

16. Bob W. van Roozendaal and Ines Krass. Development of an evidence-based checklist for the detection of drug related problems in type 2 diabetes. Pharm World Sci, 2009; 31: 580 – 595.